Viridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officer
16 2월 2024 - 10:00PM
Business Wire
Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the “company” or
“Viridian”), a biopharmaceutical company focused on discovering and
developing potential best-in-class medicines for serious and rare
diseases, today announced the appointment of Jennifer Tousignant to
the role of Chief Legal Officer.
“I am very pleased to welcome Jennifer to Viridian to lead our
legal team and join Viridian’s executive team ahead of an exciting
set of milestones this year across our thyroid eye disease and
anti-neonatal Fc receptor portfolios,” said Steve Mahoney, Viridian
President and Chief Executive Officer. “With Jennifer’s deep
expertise and long history in public biotech companies advising on
a broad set of business and legal matters, she will be a great
complement and asset to the team as we execute on our corporate
priorities.”
Ms. Tousignant joins Viridian most recently from Sana
Biotechnology where she was Senior Vice President of Legal and led
the legal team responsible for research and development,
regulatory, quality, intellectual property, business development,
corporate communications and investor relations, and litigation.
She joined Sana from Xilio Therapeutics where she was the Head of
Legal and responsible for all legal and compliance matters. Prior
to Xilio, Jennifer was Chief Intellectual Property Counsel at
TESARO, Inc., where she built and led the intellectual property
function and was a key member of the global launch teams for
several products. Early in her career, she worked at Genzyme
Corporation in roles of increasing responsibility in research and
in legal. She received her J.D. from Suffolk University School of
Law, magna cum laude, and her B.A. in Chemistry with Honors from
the University of Virginia.
“I am thrilled to join Viridian during this transformational
time,” said Ms. Tousignant. “I look forward to working closely with
the team to execute and deliver on a portfolio of differentiated
and potentially best-in-class medicines for patients. This is an
incredibly exciting time for Viridian, and I am excited to
contribute.”
Notice of Issuance of Inducement
Grants
Viridian also announced that the company’s Board of Directors
approved the grant of non-qualified stock options to Ms. Tousignant
to purchase up to 290,000 shares of the company’s common stock (the
“Inducement Grant”) on February 12, 2024 (the “Grant Date”). The
Inducement Grant has been granted outside of the company’s Amended
and Restated 2016 Equity Incentive Plan (the “Plan”) but remains
subject to the terms and conditions of such Plan. The Inducement
Grant was granted as an inducement material to Ms. Tousignant
entering into employment with Viridian in accordance with Nasdaq
Listing Rule 5635(c)(4).
The Inducement Grant has an exercise price per share that is
equal to the closing price of Viridian’s common stock on the Grant
Date. The Inducement Grant will vest over a four-year period, with
25% of the shares vesting on the one-year anniversary of the Ms.
Tousignant’s start date, and thereafter the remainder of the shares
vest in 36 equal monthly installments, subject to Ms. Tousignant’s
continued employment with Viridian through the applicable vesting
dates.
About Viridian Therapeutics
Viridian is a biopharmaceutical company focused on engineering
and developing potential best-in-class medicines for patients with
serious and rare diseases. Viridian’s expertise in antibody
discovery and engineering enables it to develop differentiated
therapeutic candidates for previously validated drug targets in
commercially established disease areas.
Viridian is advancing multiple candidates in the clinic for the
treatment of patients with thyroid eye disease (TED). The company
is conducting two global Phase 3 clinical trials (THRIVE and
THRIVE-2) to evaluate the safety and efficacy of VRDN-001 in
patients with active and chronic TED. Viridian’s goal is to advance
VRDN-001 as a best-in-class IV therapy followed by VRDN-003 as a
first- and best-in-class subcutaneous therapy for the treatment of
TED.
In addition to its TED portfolio, Viridian is advancing a novel
portfolio of neonatal Fc receptor (FcRn) inhibitors, VRDN-006 and
VRDN-008, which has the potential to be developed in multiple
autoimmune diseases.
Viridian is based in Waltham, Massachusetts. For more
information, please visit www.viridiantherapeutics.com. Follow
Viridian on LinkedIn and X.
Source: Viridian Therapeutics, Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240215293347/en/
Louisa Stone, 617-272-4604 Manager, Investor Relations
IR@viridiantherapeutics.com
Viridian Therapeutics (NASDAQ:VRDN)
과거 데이터 주식 차트
부터 8월(8) 2024 으로 9월(9) 2024
Viridian Therapeutics (NASDAQ:VRDN)
과거 데이터 주식 차트
부터 9월(9) 2023 으로 9월(9) 2024